The effect of mizolastine on expression of vascular endothelial cell growth factor, tumour necrosis factor-alpha and keratinocyte-derived chemokine in murine mast cells, compared with dexamethasone and loratadine
- 1 March 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical and Experimental Dermatology
- Vol. 30 (2) , 165-170
Abstract
It has been shown that many antihistamines may have anti-inflammatory activity in addition to being H1 antagonists. Mizolastine (MIZ), a novel antihistamine, might also have anti-angiogenesis properties. In this study, we investigated the influence of MIZ on proangiogenesis factors, vascular endothelial cell growth factor (VEGF), tumour necrosis factor (TNF)-alpha and keratinocyte-derived chemokine (KC) in murine mast cells by using ELISA and RT-PCR, as compared with dexamethasone (DEX) and loratadine (LOR). Our results show that MIZ is effective in the inhibition of KC, VEGF and TNF-alpha release induced by an IgE-dependent mechanism, in a time- and dose-dependent manner. The differences between the inhibitory effects of the three drugs on these proangiogenic factors were rather subtle. Semiquantitative analysis using RT-PCR showed that the three drugs significantly reduced VEGF165, VEGF120, TNF-alpha and KC mRNA expression. Statistical results revealed that the effect of DEX on VEGF165 mRNA was different from that of MIZ or LOR (P < 0.01) and the differences between the three drugs on VEGF120, TNF-alpha and KC mRNA were not statistically significant (P > 0.05). These findings raise the possibility that MIZ can mediate anti-angiogenesis activity and that the effect may depend not only on the inhibition on the levels of cytokine proteins but also at the mRNA level.Keywords
This publication has 12 references indexed in Scilit:
- In vivo leukocyte cytokine mRNA responses to biomaterials are dependent on surface chemistryJournal of Biomedical Materials Research Part A, 2002
- Increased expression of vascular endothelial growth factor in placentas of p57Kip2 null embryosFEBS Letters, 2002
- Inhibition of mediator and cytokine release from dispersed nasal polyp cells by mizolastineAllergy, 2002
- Role of mediators in late-phase allergic symptoms including congestionClinical & Experimental Allergy Reviews, 2002
- Mast cells and angiogenesisAPMIS, 2002
- Comparative activity of cetirizine and mizolastine on histamine‐induced skin wheal and flare responses at 24 hBritish Journal of Clinical Pharmacology, 2002
- A Potential Role for Mast Cells in the of bFGF From Normal Myocytes During Angiogenesis In VivoJournal of Investigative Surgery, 2002
- Inhibition of cytokine generation and mediator release by human basophils treated with desloratadineClinical & Experimental Allergy, 2001
- Mast cells and angiogenesisClinical & Experimental Allergy, 2001
- Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1‐ and H2‐receptor antagonistsExperimental Dermatology, 2000